Peptide LexiconAll compounds

Insulin: The 51-Amino-Acid Hormone, Its Two Chains, and the 37 US Applications That Carry It

Insulin is a 51-amino-acid hormone made by the pancreas: two chains, 21 and 30 residues, joined by two disulfide bridges. It lowers blood glucose. It has been a medicine since the 1920s, and FDA's database listed 37 applications containing an insulin on 2026-11-13. This entry sets out the molecule, the label figures and the approval record.

Approved medicineEndogenous hormoneA small protein by FDA's 40-residue line

Caroline S · Published 2026-11-13

Length

51 amino acids in two chains — A chain 21, B chain 30; C257H383N65O77S6, molecular weight 5,808 (PubChem CID 118984375; Humulin R label)

Sequence

A chain GIVEQCCTSICSLYQLENYCN · B chain FVNQHLCGSHLVEALYLVCGERGFFYTPKT (UniProt P01308)

Origin

Made by the beta cells of the pancreas from a 110-residue precursor; the medicine is made by recombinant DNA technology

Last reviewed

2026-11-13

What is it good for?

Insulin is the hormone that lowers blood glucose, and as a medicine it is approved to improve glycaemic control in people with diabetes mellitus. That is a measured, approved use, not a claim: the US label for one human insulin states the indication for adults and children. The same label names hypoglycaemia — blood glucose falling too low — as the most commonly observed adverse reaction and says it may be life-threatening.

Illustration: A clear glass Erlenmeyer flask with pale green liquid on a white lab bench.
Illustration

What it is

Insulin is a hormone made of 51 amino acids arranged in two chains. The A chain has 21 residues and the B chain has 30. Two disulfide bridges — bonds between sulfur atoms on cysteine residues — hold the chains together, and a third sits inside the A chain (UniProt P01308, read 2026-11-13).

The beta cells of the pancreas do not build it as two chains. They make one 110-residue precursor: a 24-residue signal piece, the B chain, a 31-residue connecting piece, and the A chain. The signal piece and the connecting piece are cut away. The connecting piece is C-peptide, which is released alongside insulin and measured as a marker of the body's own production.

Is it a peptide or a protein? At 51 residues it sits above the 40-residue line FDA uses, and every insulin application in FDA's database is a biologics licence. The peptide-versus-protein entry explains where that line comes from. Chemically it is a short pair of peptide chains, which is why older texts call it a peptide hormone.

Property Value Source
A chain 21 residues, GIVEQCCTSICSLYQLENYCN UniProt P01308
B chain 30 residues, FVNQHLCGSHLVEALYLVCGERGFFYTPKT UniProt P01308
Disulfide bridges 3 (2 between chains, 1 inside the A chain) UniProt P01308
Formula C257H383N65O77S6 PubChem CID 118984375; Humulin R label
Molecular weight 5,808 PubChem; label states 5.808 kDa

The six sulfur atoms in the formula are the six cysteines that form the three bridges (our reading of the sequence: four cysteines in the A chain, two in the B chain).

What it does

The label for Humulin R, a regular human insulin, describes the mechanism in three statements. Insulin lowers blood glucose by stimulating glucose uptake, especially by skeletal muscle and fat. It inhibits glucose production by the liver. And it inhibits the breakdown of fat and protein while enhancing protein synthesis.

Its opposite number is glucagon, the hormone that raises blood glucose. The gut hormones that prompt the pancreas to release insulin after a meal are described under the incretin entry. Whether a GLP-1 medicine is an insulin is a separate question, answered on GLP1Ledger's page on GLP-1 and insulin.

What a label states

These figures come from one label — Humulin R U-100, the version dated 2023-10-31 in openFDA's label file. They describe that product and are reported here, not offered as guidance. Other insulins are engineered to act faster or longer and carry different figures.

Measure Figure on the Humulin R label
Indication To improve glycaemic control in adult and paediatric patients with diabetes mellitus
Strength 100 units per millilitre (U-100)
Onset under the skin About 30 minutes (range 10 to 75 minutes)
Maximum effect About 3 hours (range 20 minutes to 7 hours)
End of effect About 8 hours (range 3 to 14 hours)
Half-life under the skin About 1.5 hours (range 40 minutes to 7 hours)
Absorbed from under the skin 48% to 89%
Contraindications During episodes of hypoglycaemia; hypersensitivity to the product
Most common adverse reaction Hypoglycaemia

The label's warnings also name hypokalaemia (low blood potassium), severe allergic reactions, and mix-ups between insulin products. It states that the time course "may vary considerably in different individuals or within the same individual."

The approval record

FDA's drug database, in the openFDA copy dated 2026-11-10, held 37 applications with an insulin as an active ingredient when this entry read it on 2026-11-13. The count includes human insulin, engineered analogues, pre-mixed products and two combinations with a GLP-1 medicine. To check that the search worked, the same query for glucagon returned 12 applications.

Date approved Product What it marked
1982-10-28 Humulin R, Humulin N (Lilly) First recombinant human insulins in the database
1991-06-25 Novolin R (Novo Nordisk) A second maker's human insulin
1996-06-14 Humalog (insulin lispro) Earliest engineered analogue in the list
2000-04-20 Lantus (insulin glargine) Earliest insulin glargine in the list
2014-06-27 Afrezza Inhaled human insulin
2021-07-28 Semglee (insulin glargine-yfgn), BLA761201 A second Semglee licence; the first is dated 2020-06-11
2026-03-26 Awiqli (insulin icodec) Among the four approvals dated 2026
2026-09-23 Onswik (insulin efsitora alfa) Newest in the list; label indication is adults with type 2 diabetes

Two details from the same data. Six of the human-insulin applications — the Humulin and Novolin lines — carry the marketing status "Over-the-counter" as well as or instead of "Prescription". And the Onswik label says the product is not recommended in type 1 diabetes "due to increased risk of severe hypoglycemia."

A short history

  • 1923: the Nobel Prize in Physiology or Medicine went to Frederick Banting and John Macleod "for the discovery of insulin" (Nobel Prize records).
  • 1958: Frederick Sanger received the Nobel Prize in Chemistry "for his work on the structure of proteins, especially that of insulin."
  • 1982: the first recombinant human insulins were approved in the United States.

What this entry does not cover

  • Which insulin suits which person, and in what amount. Those are prescribing decisions, and the labels themselves say changes should be made under close medical supervision.
  • Insulin prices and coverage.
  • Use outside diabetes care. No approved label read for this entry describes one.

Where it stands

  • Approved: yes, in many forms; 37 applications in FDA's database (2026-11-13).
  • Classed as: a biologic in the United States.
  • Research record: PubMed 170,547 title records, 7,795 of them tagged as randomised controlled trials; ClinicalTrials.gov 8,255 studies with an insulin as an intervention (2026-11-13).

The growth factor named for its resemblance to insulin is described in the IGF-1 entry. Amylin, the second hormone released by the same pancreatic cells, and pramlintide, the medicine copied from amylin, sit beside insulin in diabetes care. For the wider family of gut and pancreas signals, see the GLP-1 entry.

What the research shows

Lowers blood glucose in people with diabetes

Approved indication on US labels (Humulin R label, version dated 2023-10-31 in openFDA); PubMed holds 7,795 randomised-trial records with insulin in the title (2026-11-13)

Acts within about 30 minutes under the skin and for about 8 hours (regular human insulin)

Humulin R label, pharmacodynamics: onset about 30 minutes (range 10 to 75), maximum about 3 hours, end about 8 hours (range 3 to 14)

Can be given by inhalation

Afrezza, an inhaled human insulin, approved 2014-06-27 (Drugs@FDA BLA022472); its label carries a boxed warning on acute bronchospasm in chronic lung disease

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

FDA

37 applications contain an insulin as an active ingredient in FDA's drug database (openFDA copy dated 2026-11-10, read 2026-11-13); every one is filed as a biologics licence (BLA).

First recombinant approval

Humulin R and Humulin N, Eli Lilly, 1982-10-28 (BLA018780, BLA018781).

Newest approvals

Awiqli (insulin icodec) 2026-03-26; Langlara 2026-04-29; Garzulys 2026-07-24; Onswik (insulin efsitora alfa) 2026-09-23.

Published record

PubMed: 170,547 records with insulin in the title; ClinicalTrials.gov: 8,255 studies listing an insulin as an intervention (2026-11-13).

Frequently asked questions

What is insulin?

A hormone made by the beta cells of the pancreas. It is a chain-pair of 51 amino acids — 21 in the A chain, 30 in the B chain — and its main action is to lower blood glucose.

Is insulin a peptide or a protein?

Both words are used. Biochemists often call it a peptide hormone. At 51 amino acids it sits above the 40-residue line FDA uses to separate peptides from proteins, and FDA's database files every insulin product as a biologic.

What does insulin do in the body?

A US insulin label puts it this way: insulin lowers blood glucose by stimulating glucose uptake, especially by skeletal muscle and fat, and by inhibiting glucose production in the liver. It also inhibits the breakdown of fat and protein and enhances protein synthesis.

How is insulin made as a medicine?

By recombinant DNA technology. The Humulin R label states that its insulin human is produced in a non-pathogenic laboratory strain of Escherichia coli.

What is the most common side effect of insulin?

Hypoglycaemia — blood glucose falling too low. The Humulin R label calls it the most commonly observed adverse reaction and says it may be life-threatening. Decisions about insulin treatment belong with the prescribing clinician.

What is the difference between insulin and C-peptide?

They are cut from one precursor. The pancreas makes proinsulin, removes a 31-residue connecting piece called C-peptide, and releases both. Insulin is the active hormone; C-peptide is measured in blood as a sign of how much insulin the body is making itself.